ACT004 Ovatodiolide Derivative for Renal Fibrosis Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for renal fibrosis (RF) associated with chronic kidney disease (CKD) are inadequate, with existing therapies either ineffective or associated with significant side effects, leading to progression to end-stage renal disease (ESRD) and high economic burden.
Innovation Solution
The use of an ovatodiolide derivative (ACT004) to inhibit the TGF-β1/Smad, STAT3, and NF-κB signaling pathways, thereby suppressing epithelial-mesenchymal transdifferentiation (EMT) in renal tubular epithelial cells, reducing ECM deposition, and delaying renal fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RAAS blockers are used to delay CKD progression, then renal protective effect is improved, but hyperkalemia and acute kidney injury occur
Solution Approach 1:
The patent extracts and targets specific molecular pathways (TGF-β1/Smad, STAT3, NF-κB) involved in renal fibrosis, separating the therapeutic action from the harmful side effects of conventional RAAS blockers. By directly inhibiting fibrotic pathways rather than broadly blocking renin-angiotensin-aldosterone system, the treatment achieves renal protection without inducing hyperkalemia or acute kidney injury.
Solution Approach 2:
The patent changes the therapeutic parameter from hemodynamic control (RAAS blockade) to molecular pathway inhibition (TGF-β1/Smad, STAT3, NF-κB). This parameter change allows selective targeting of fibrotic processes while avoiding the electrolyte disturbances and acute kidney injury associated with conventional approaches.
2Reliability
If SGLT-2 inhibitors are used for renal protection, then renal protective effect is improved, but application is limited in middle and later stages of CKD
Solution Approach 1:
The patent develops a multi-target inhibitor that addresses multiple fibrotic pathways (TGF-β1/Smad, STAT3, NF-κB) simultaneously, creating a universal treatment applicable across different CKD stages including middle and later stages where SGLT-2 inhibitors are limited. This multi-functional approach allows the same mechanism to benefit patients regardless of disease stage.
3Ease of manufacture
If molecular mechanism-based anti-RF treatments are developed, then targeted therapy is improved, but clinical trials end with failure
Solution Approach 1:
The patent employs a composite therapeutic strategy that simultaneously targets three interconnected fibrotic pathways (TGF-β1/Smad, STAT3, NF-κB) rather than a single pathway. This composite approach addresses the complexity of renal fibrosis by blocking multiple downstream effectors of TGF-β1 signaling, thereby increasing the likelihood of clinical success compared to single-pathway inhibitors that have previously failed.
4Ease of manufacture
If conventional anti-RF treatments are used, then some molecular targets are addressed, but ECM deposition and fibrosis progression continue
Solution Approach 1:
The patent merges inhibition of three key fibrotic pathways (TGF-β1/Smad, STAT3, NF-κB) into a single therapeutic approach. By combining these targeted inhibitions, the treatment achieves comprehensive blockade of extracellular matrix deposition and fibrosis progression, overcoming the insufficient efficacy of single-pathway targeted therapies.
Data Source
AI summary
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof can be used in the preparation of a medicament for treating and/or preventing renal fibrosis and/or renal diseases related to renal fibrosis. The compound represented by formula (I) has a structure as follows: